DBV Technologies S.A. (DBVT)

Market Cap	793.00M +217.7%
Revenue (ttm)	5.04M +33.1%
Net Income	-175.95M
EPS	-0.60
Shares Out	295.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,033
Open	13.42
Previous Close	13.70
Day's Range	13.30 - 13.58
52-Week Range	8.70 - 26.19
Beta	-0.24
Analysts	Buy
Price Target	41.47 (+207.87%)
Earnings Date	Jul 16, 2026

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 126
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT
• Website: https://www.dbv-technologies.com

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price target is $41.47, which is an increase of 207.87% from the latest price.

Price Target

$41.47

(207.87% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 5, 2026

Data Sources Report a data error